Inventor · disambiguated record
Shimobi Onuoha
Also filed as: ONUOHA SHIMOBI
33 granted patents·31 pending applications·87 citations·filing 2013–2025
96Inventor score
Top patents by PatentIndex Score
64 records- 0196US11034750B2Chimeric antigen receptor (CAR) comprising a CD19-binding domainAUTOLUS LTD·Filed 2018·Granted Jun 15, 2021·8 cites·7 claims
- 0295US12187769B2CellAUTOLUS LTD·Filed 2023·Granted Jan 7, 2025·2 cites·5 claims
- 0395US11091532B2T cell which co-expresses a CD19 chimeric antigen receptor and a CD22 chimeric antigen receptorAUTOLUS LTD·Filed 2015·Granted Aug 17, 2021·8 cites·16 claims
- 0494US11590170B2Chimeric antigen receptorAUTOLUS LTD·Filed 2022·Granted Feb 28, 2023·3 cites·6 claims
- 0594US11434293B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2021·Granted Sep 6, 2022·7 cites·10 claims
- 0693US10981970B2Chimeric antigen receptor (CAR) comprising a CD22-binding domainAUTOLUS LTD·Filed 2018·Granted Apr 20, 2021·4 cites·8 claims
- 0793US10800854B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2016·Granted Oct 13, 2020·6 cites·22 claims
- 0893US10098926B2CellUCL BUSINESS PLC·Filed 2017·Granted Oct 16, 2018·10 cites·4 claims
- 0992US11440961B2Anti TRBC1 antigen binding domainsAUTOLUS LTD·Filed 2018·Granted Sep 13, 2022·7 cites·11 claims
- 1092US10800855B2Chimeric cytokine receptors and encoding nucleic acidsAUTOLUS LTD·Filed 2018·Granted Oct 13, 2020·4 cites·15 claims
- 1190US10174099B2CellUCL BUSINESS PLC·Filed 2017·Granted Jan 8, 2019·5 cites·3 claims
- 1289US2025353893A1CellAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 1387US12049510B2Chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Jul 30, 2024·2 cites·14 claims
- 1487US11180553B2Chimeric antigen receptorAUTOLUS LTD·Filed 2017·Granted Nov 23, 2021·4 cites·12 claims
- 1587US10131709B2Nucleic acid molecules encoding monoclonal antibodies specific for IL-22IMMUNOQURE AG·Filed 2016·Granted Nov 20, 2018·4 cites·21 claims
- 1686US12398194B2Cell lexpressing two chimeric antigen receptors (CARs) at the cell surfaceAUTOLUS LTD·Filed 2023·Granted Aug 26, 2025·0 cites·20 claims
- 1786US11479613B2Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteinsAUTOLUS LTD·Filed 2020·Granted Oct 25, 2022·1 cites·11 claims
- 1883US12234295B2Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereofAUTOLUS LTD·Filed 2022·Granted Feb 25, 2025·0 cites·22 claims
- 1983US11701386B2CellAUTOLUS LTD·Filed 2018·Granted Jul 18, 2023·1 cites·7 claims
- 2083US10081676B2Human anti-IL-32 antibodies and methods of making and using the sameIMMUNOQURE AG·Filed 2014·Granted Sep 25, 2018·4 cites·35 claims
- 2181US2025197464A1CellAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 2280US9475872B2Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17FIMMUNOQURE AG·Filed 2013·Granted Oct 25, 2016·5 cites·22 claims
- 2380US2025277047A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 2479US11466070B2Signalling systemAUTOLUS LTD·Filed 2017·Granted Oct 11, 2022·2 cites·12 claims
- 2578US12454578B2Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptorsAUTOLUS LTD·Filed 2022·Granted Oct 28, 2025·0 cites·4 claims
- 2678US2025019434A1Chimeric antigen receptorAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 2777US2025333505A1T-cell receptor constant region 1 antibody or t-cell receptor constant region 2 antibodyAUTOLUS LTD·Filed 2024·Application pending·0 cites
- 2877US2025333538A1Chimeric cytokine receptorAUTOLUS LTD·Filed 2025·Application pending·0 cites
- 2974US12492410B2Engineered cytolytic immunecellAUTOLUS LTD·Filed 2022·Granted Dec 9, 2025·0 cites·6 claims
- 3074US11479614B2Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptorsAUTOLUS LTD·Filed 2020·Granted Oct 25, 2022·0 cites·27 claims
- 3174US2020181232A1CellAUTOLUS LTD·Filed 2020·Application pending·0 cites
- 3270US11963981B2Chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Apr 23, 2024·0 cites·16 claims
- 3368US11945867B2T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibodyAUTOLUS LTD·Filed 2019·Granted Apr 2, 2024·0 cites·11 claims
- 3462US10875916B2Nucleic acid molecules encoding monoclonal antibodies specific for IL-17FIMMUNOQURE AG·Filed 2018·Granted Dec 29, 2020·0 cites·24 claims
- 3562US2025353931A1Multi-specific reagent for targeted delivery of lipid nanoparticlesCHIMERIS UK LTD·Filed 2025·Application pending·0 cites
- 3661US11648274B2PolypeptideAUTOLUS LTD·Filed 2018·Granted May 16, 2023·0 cites·29 claims
- 3761US2021032655A1Engineered cytolytic immunecellAUTOLUS LTD·Filed 2019·Application pending·0 cites
- 3859US2025289891A1Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseasesAUTOLUS LTD·Filed 2022·Application pending·0 cites
- 3957US2025381224A1Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3AUTOLUS LTD·Filed 2025·Application pending·0 cites
- 4056US2024408134A1CellAUTOLUS LTD·Filed 2021·Application pending·0 cites
- 4156US2023330139A1Car t-cells comprising an anti cd33, an anti cll1 and at least one further car anti cd123 and/or ftl3AUTOLUS LTD·Filed 2019·Application pending·0 cites
- 4254US10975144B2CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of the antibodyIMMUNOQURE AG·Filed 2018·Granted Apr 13, 2021·0 cites·20 claims
- 4354US2023109275A1Trbc beta antibody conjugateAUTOLUS LTD·Filed 2021·Application pending·0 cites
- 4453US2023233606A1CellAUTOLUS LTD·Filed 2020·Application pending·0 cites
- 4553US2024091357A1Engineered immune cellAUTOLUS LIMIRED·Filed 2020·Application pending·0 cites
- 4652US12241068B2CD79-specific chimeric antigen receptorAUTOLUS LTD·Filed 2019·Granted Mar 4, 2025·0 cites·3 claims
- 4752US2021363217A1CellAUTOLUS LTD·Filed 2019·Application pending·0 cites
- 4851US2023293647A1PolypeptideAUTOLUS LTD·Filed 2021·Application pending·0 cites
- 4951US2022211830A1CellAUTOLUS LTD·Filed 2020·Application pending·0 cites
- 5051US2022242965A1Engineered t-cells co-expressing an anti-bcma car and an anti-ectoenzyme antibody and their use in the treatment of cancerAUTOLUS LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Shimobi Onuoha files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →